KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Gains from Investment Securities: 2016-2024

Historic Gains from Investment Securities for Moderna (MRNA) over the last 8 years, with Dec 2024 value amounting to $197.0 million.

  • Moderna's Gains from Investment Securities fell 112.73% to -$14.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.0 million, marking a year-over-year increase of 128.02%. This contributed to the annual value of $197.0 million for FY2024, which is 155.18% up from last year.
  • Per Moderna's latest filing, its Gains from Investment Securities stood at $197.0 million for FY2024, which was up 155.18% from -$357.0 million recorded in FY2023.
  • Moderna's 5-year Gains from Investment Securities high stood at $2.7 billion for FY2022, and its period low was -$357.0 million during FY2023.
  • Its 3-year average for Gains from Investment Securities is $856.3 million, with a median of $197.0 million in 2024.
  • Per our database at Business Quant, Moderna's Gains from Investment Securities soared by 5,900.00% in 2021 and then tumbled by 113.08% in 2023.
  • Yearly analysis of 5 years shows Moderna's Gains from Investment Securities stood at $8.0 million in 2020, then surged by 5,900.00% to $480.0 million in 2021, then spiked by 468.54% to $2.7 billion in 2022, then plummeted by 113.08% to -$357.0 million in 2023, then soared by 155.18% to $197.0 million in 2024.